These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16420394)

  • 1. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting.
    Karussis D; Biermann LD; Bohlega S; Boiko A; Chofflon M; Fazekas F; Freedman M; Gebeily S; Gouider R; Havrdova E; Jakab G; Karabudak R; Miller A;
    Eur J Neurol; 2006 Jan; 13(1):61-71. PubMed ID: 16420394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization.
    Correale J; Abad P; Alvarenga R; Alves-Leon S; Armas E; Barahona J; Buzó R; Corona T; Cristiano E; Gracia F; Bonitto JG; Macías MA; Soto A; Vizcarra D; Freedman MS
    J Neurol Sci; 2014 Apr; 339(1-2):196-206. PubMed ID: 24607335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C; Ruggieri S
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.
    Rudick RA; Polman CH
    Lancet Neurol; 2009 Jun; 8(6):545-59. PubMed ID: 19446274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs.
    Miller AE; Rhoades RW
    Curr Opin Neurol; 2012 Feb; 25 Suppl():S4-10. PubMed ID: 22398662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command.
    Freedman MS; Cohen B; Dhib-Jalbut S; Jeffery D; Reder AT; Sandberg-Wollheim M; Weinstock-Guttman B
    Curr Med Res Opin; 2009 Oct; 25(10):2459-70. PubMed ID: 19678753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the management of multiple sclerosis relapses.
    Laplaud D; Bodiguel E; Bensa C; Blanc F; Brassat D; Magy L; Ouallet JC; Zephir H; De Seze J;
    Rev Neurol (Paris); 2012 May; 168(5):425-33. PubMed ID: 22555010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current evidence and therapeutic strategies for multiple sclerosis.
    Wingerchuk DM
    Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New therapeutic options in multiple sclerosis].
    Salmen A; Chan A
    Fortschr Neurol Psychiatr; 2015 Mar; 83(3):174-86. PubMed ID: 25794324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pearls: multiple sclerosis.
    Frohman EM; Greenberg BM
    Semin Neurol; 2010 Feb; 30(1):97-101. PubMed ID: 20127590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future treatments for relapsing-remitting multiple sclerosis.
    Birnbaum G
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):214-25. PubMed ID: 20205055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Potential of Computational Modeling to Predict Disease Course and Treatment Response in Patients with Relapsing Multiple Sclerosis.
    Pappalardo F; Russo G; Pennisi M; Parasiliti Palumbo GA; Sgroi G; Motta S; Maimone D
    Cells; 2020 Mar; 9(3):. PubMed ID: 32121606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: a predictive model.
    Scott TF; Hackett CT; Quigley MR; Schramke CJ
    Clin Neurol Neurosurg; 2014 Dec; 127():86-92. PubMed ID: 25459249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging.
    Rovaris M; Filippi M
    Neurol Sci; 2005 Dec; 26 Suppl 4():S204-8. PubMed ID: 16388359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of therapies other than disease-modifying agents, including complementary and alternative medicine, by patients with multiple sclerosis: a survey study.
    Stoll SS; Nieves C; Tabby DS; Schwartzman R
    J Am Osteopath Assoc; 2012 Jan; 112(1):22-8. PubMed ID: 22302743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging oral therapies for multiple sclerosis.
    Cohen BA; Rieckmann P
    Int J Clin Pract; 2007 Nov; 61(11):1922-30. PubMed ID: 17784852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients.
    Heigl F; Hettich R; Arendt R; Durner J; Koehler J; Mauch E
    Atheroscler Suppl; 2013 Jan; 14(1):167-73. PubMed ID: 23357160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.